These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
81 related items for PubMed ID: 8511992
1. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. J Bone Miner Res; 1993 May; 8(5):643-8. PubMed ID: 8511992 [Abstract] [Full Text] [Related]
2. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936 [Abstract] [Full Text] [Related]
3. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. Garnero P, Gineyts E, Riou JP, Delmas PD. J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361 [Abstract] [Full Text] [Related]
4. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812 [Abstract] [Full Text] [Related]
5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094 [Abstract] [Full Text] [Related]
6. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM. J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468 [Abstract] [Full Text] [Related]
7. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Arbault P, Grimaux M, Pradet V, Preaudat C, Seguin P, Delmas PD. Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707 [Abstract] [Full Text] [Related]
8. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP. J Bone Miner Res; 1994 Sep; 9(9):1433-40. PubMed ID: 7817828 [Abstract] [Full Text] [Related]
9. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods]. Meddah B, Brazier M, Kamel S, Maamer M, Samson L, Desmet G, Sebert JL. Ann Biol Clin (Paris); 1996 Sep; 54(10-11):353-8. PubMed ID: 9092303 [Abstract] [Full Text] [Related]
10. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease. Naylor KE, Jackson B, Eastell R. J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326 [Abstract] [Full Text] [Related]
11. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. Ohishi T, Takahashi M, Kawana K, Aoshima H, Hoshino H, Horiuchi K, Kushida K, Inoue T. Clin Invest Med; 1993 Oct; 16(5):319-25. PubMed ID: 8261685 [Abstract] [Full Text] [Related]
12. Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. Schlemmer A, Hassager C, Pedersen BJ, Christiansen C. J Bone Miner Res; 1994 Dec; 9(12):1883-8. PubMed ID: 7872053 [Abstract] [Full Text] [Related]
13. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone? Hamdy NA, Papapoulos SE, Colwell A, Eastell R, Russell RG. Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934 [Abstract] [Full Text] [Related]
14. [Effect of clodronate in patients with multiple myeloma. Evaluation of specific markers of bone resorption]. Slabý J, Spicka I, Hulejová H, Spacek P, Cieslar P, Klener P. Cas Lek Cesk; 1997 Jan 22; 136(2):57-60. PubMed ID: 9147856 [Abstract] [Full Text] [Related]
15. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate. Constantin A, Laroche M, Moulinier L, Bon E, Ramonjisoa M, Cantagrel A, Mazieres B. Rev Rhum Engl Ed; 1995 Jan 22; 62(7-8):493-500. PubMed ID: 8574612 [Abstract] [Full Text] [Related]
16. Comparison of immuno- and HPLC-assays for the measurement of urinary collagen cross-links. Calabresi E, Lasagni L, Franceschelli F, de Leonardis V, Becorpi A, Serio M, Brandi ML. J Endocrinol Invest; 1994 Sep 22; 17(8):625-9. PubMed ID: 7868800 [Abstract] [Full Text] [Related]
17. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. J Bone Miner Res; 1992 Dec 22; 7(12):1389-98. PubMed ID: 1481725 [Abstract] [Full Text] [Related]
18. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. J Clin Endocrinol Metab; 1991 Feb 22; 72(2):367-73. PubMed ID: 1991806 [Abstract] [Full Text] [Related]
19. Immunoassay for urinary pyridinoline: the new marker of bone resorption. Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, Rosen HN, Zuk RF. J Bone Miner Res; 1993 May 22; 8(5):635-41. PubMed ID: 8511991 [Abstract] [Full Text] [Related]
20. The renal clearance of free and conjugated pyridinium cross-links of collagen. Colwell A, Eastell R. J Bone Miner Res; 1996 Dec 22; 11(12):1976-80. PubMed ID: 8970901 [Abstract] [Full Text] [Related] Page: [Next] [New Search]